Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost

Diamond Hill Capital, a First Eagle Investment Management company, included BioLife Solutions, Inc. (NASDAQ:BLFS), a biotechnology firm specializing in cell and gene therapy products and services, in its Q2 2026 Small Cap Strategy letter. The investment firm initiated a position in BioLife Solutions, Inc. (NASDAQ:BLFS) during the quarter, citing the company's distinct advantage in the space due to the difficulty of switching providers.

This advantage stems from validation requirements, regulatory filings, and complex manufacturing processes associated with BioLife Solutions, Inc. (NASDAQ:BLFS)'s biopreservation media. The firm believes the company's bioproduction products and services are essential materials for manufacturing, storing, and transporting living human cells.